4595.T
MIZUHO MEDY CO.,LTD.
スタンダード · 医薬品 · 医薬品 · JP
JPY 1,715.00
−0.46%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.8B | 11.3B | 11.4B | 11.0B | 17.6B |
| Cost of Revenue | 698.0M | — | — | — | — |
| Gross Profit | 1.5B | 7.8B | 8.1B | 8.1B | 14.1B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 750.0M | 3.2B | 3.2B | 2.9B | 3.0B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 750.0M | 3.2B | 3.2B | 2.9B | 3.0B |
| Cost and Expenses | 6.5B | 6.6B | 6.5B | 5.8B | 6.5B |
| Operating Income (EBIT) | 4.3B | 4.6B | 4.9B | 5.2B | 11.1B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | 90.0M | — | — | (33.3M) |
| Non-Operating Income (excl Interest) | 1.0M | 2.0M | 2.0M | 735.0K | 572.0K |
| EBT (Pre-Tax Income) | 823.0M | 4.7B | 5.2B | 5.3B | 11.1B |
| Income Tax Expense | 222.0M | 1.3B | 1.4B | 1.5B | 3.2B |
| Bottom Line | |||||
| Net Income | 3.2B | 3.4B | 3.8B | 3.8B | 7.8B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 3.2B | 3.4B | 3.8B | 3.8B | 7.8B |
| Per Share | |||||
| Basic EPS | ¥171 | ¥180 | ¥198 | ¥396 | ¥823 |
| Diluted EPS | ¥171 | — | — | — | — |
| Revenue Per Share | ¥568 | ¥591 | ¥600 | ¥1,154 | ¥1,846 |
| Shares | |||||
| Basic Shares Outstanding | 19.0M | 19.0M | 19.0M | 9.5M | 9.5M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 4.9B | 5.1B | 5.3B | 11.3B |
| D&A | — | 266.0M | 228.0M | 195.5M | 186.6M |
| EBIT | 4.3B | 4.6B | 4.9B | 5.2B | 11.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026